Brief: Vincerx Pharma Presents Preclinical Data On Vip236, A First-In-Class Small Molecule Drug Conjugate (Smdc), At The 2023 American Association For Cancer Research (Aacr) Annual Meeting
17/04/2023 13:04
April 17 (Reuters) - Vincerx Pharma Inc VINC.O :
* VINCERX PHARMA PRESENTS PRECLINICAL DATA ON VIP236, A
FIRST-IN-CLASS SMALL MOLECULE DRUG CONJUGATE (SMDC), AT THE 2023
AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING
Source text for Eikon: ID:nGNX8Zpwfj
Further company coverage: VINC.O
Recent news on Vincerx Pharma
See all newsBrief: Vincerx Pharma Announces Intent To Delist From Nasdaq And Deregister With The SEC
Brief: Vincerx Pharma Announces Termination Of Letter Of Intent And Board Authorization To Pursue Wind-Down Activities
Vincerx Pharma Inc reports results for the quarter ended December 31 - Earnings Summary
Vincerx Pharma Inc expected to post a loss of $3.40 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Aditxt, Natgas companies, DocuSign